Healthcare Equipment and Supplies
Company Overview of Metamark Genetics, Inc.
Metamark Genetics, Inc. develops diagnostic and prognostic tests for urology cancer care. It offers ProMark, a protein based prognostic test for prostate cancer; and Progensa, a urine-based molecular test to make informed repeat biopsy decisions. The company also provides cytology diagnostic services for diagnosis of bladder cancer; luorescence in situ hybridization, a diagnostic tool that helps to confirm patient’s cytology results; histology diagnostic services for prostate and bladder biopsy analysis and examinations; and PTEN/ERG molecular testing that predicts aggressiveness of HGPIN/atypical or low gleason score. It offers services in the areas of diagnosis and management of prostate c...
245 First Street
Cambridge, MA 02142
Founded in 2007
Key Executives for Metamark Genetics, Inc.
Chief Executive Officer, President and Director
Co-Founder and Scientific & Clinical Advisor
Chief Science Officer and Senior Vice President
Compensation as of Fiscal Year 2017.
Metamark Genetics, Inc. Key Developments
Metamark Genetics, Inc. Announces Agreement with Blue Cross and Blue Shield of Texas
Jul 12 16
Metamark Genetics, Inc. announced that effective June 1, 2016, the company signed an agreement with Blue Cross and Blue Shield of Texas to provide its members with in-network access to Metamark's offering of urology specialized diagnostics. Metamark has previously announced in-network agreements with additional large Blue Cross and Blue Shield Plans and also has agreements in place with the PPO networks in the country.
Metamark Genetics, Inc. Announces Agreement with Anthem Blue Cross Blue Shield of Georgia
Jun 7 16
Metamark Genetics, Inc. announced that effective May 25, 2016, the company has signed an agreement with Anthem Blue Cross Blue Shield (BCBS) of Georgia to provide its members with in-network access to Metamark's comprehensive suite of urology specialized diagnostic offerings.
Metamark Genetics, Inc. Announces Management Changes
Feb 25 16
Metamark Genetics, Inc. announced that Jerry Williamson has been named as the company's new President, Chief Executive Officer, and Director. Mr. Williamson succeeds Ken Weg, who will retain an active role as Chairman of Metamark's Board of Directors. Mr. Williamson joined Metamark in 2015 as Chief Commercial Officer. Prior to Metamark, Mr. Williamson was a Partner with Ventures focused on building and developing relationships with corporate partners for the firm's core innovation and investment activities. He served as Vice President and General Manager for Molecular Devices. Mr. Williamson was President of Global Commercial Operations for Genetix Ltd. and served as President of Biacore, Inc.
Similar Private Companies By Industry
Recent Private Companies Transactions
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries